KraneShares MSCI All China Health Care Index ETF (KURE)

The healthcare ETF is capturing a distinct thematic tailwind driven by China's regulatory reprieve and innovation in med-tech and cancer treatments. Fundamentally, the business quality is solid, evidenced by a robust recovery in the trailing twelve months (+15.47%) and a seven-year cumulative gain despite a mid-cycle correction. The price action confirms this reversal, trading well above its 200-day average with positive momentum building. While the statistical forecast model remains neutral due to short-term noise, the divergence between weak statistical signals and strong fundamental/momentum data suggests the latter is the correct driver here. The options market agrees, with traders betting on further appreciation rather than protection. The dividend yield is attractive but secondary to the capital appreciation potential; however, the payout history shows some volatility, preventing a top-tier yield rating. Overall, this is a compelling medium-term play on the rediscovery of China's healthcare sector.